by Plus Therapeutics | Feb 25, 2025 | LM
Plus Therapeutics Announces Key Leadership Appointments for CNSide Diagnostics, LLC We are excited to announce the appointment of Russell Bradley as President and General Manager of CNSide Diagnostics, LLC, a Plus Therapeutics subsidiary focused on advancing...
by Plus Therapeutics | Feb 20, 2025 | GBM, LM, PBC, Uncategorized
Plus Therapeutics Appoints Michael Rosol, Ph.D., as Chief Development Officer We are excited to announce the appointment of Michael Rosol, Ph.D., as Chief Development Officer at Plus Therapeutics. In this role, Dr. Rosol will oversee the company’s clinical,...
by Plus Therapeutics | Feb 18, 2025 | GBM, LM, PBC, Uncategorized
Plus Therapeutics Secures $5.7 Million in Funding to Advance Cancer Research #PSTV News: Plus Therapeutics has successfully closed a private placement with $3.7 million in upfront proceeds and received a $2.0 million advance payment from the Cancer Prevention and...
by Plus Therapeutics | Feb 11, 2025 | GBM, LM, PBC, Uncategorized
Celebrating Strength and Resilience: Patient Appreciation Month At Plus Therapeutics, we are honored to celebrate #PatientAppreciationMonth and recognize the incredible strength, resilience, and courage of patients facing cancer. 🧡 Every day, we are inspired by those...
by Plus Therapeutics | Feb 4, 2025 | GBM, LM, PBC, Uncategorized
Honoring Progress and Hope on World Cancer Day 🔬 Today is #WorldCancerDay, a day dedicated to raising awareness, advancing research, and supporting those affected by cancer. At Plus Therapeutics, we recognize the unwavering dedication of patients, caregivers, and...
by Plus Therapeutics | Feb 1, 2025 | GBM, LM, PBC, Uncategorized
A Heartfelt Thank You to Our ReSPECT-GBM & ReSPECT-LM Clinical Trial Participants To every patient who has participated in the ReSPECT-GBM and ReSPECT-LM clinical trials: THANK YOU! 💙 Your courage and commitment are helping advance critical research for recurrent...
Recent Comments